EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene therapy for aromatic L‐amino acid decarboxylase deficiency: Requirements for safe application and knowledge‐generating follow‐up

Agathe Roubertie, Thomas Opladen iD, Heiko Brennenstuhl, Oya Kuseyri Hübschmann iD, Lisa Flint, Michel A Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A Kurian, Marie Céline François-Heude, Paul Hwu, Bruria Ben Zeev und 4 weitere

Journal of Inherited Metabolic Disease · 2024-05 · 47 (3) · 463-475

DOI: 10.1002/jimd.12649 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 17.07.2023. Verfasst von Agathe Roubertie und 15 weiteren Autor:innen. Beteiligte Einrichtung: CHU Montpellier, Département de Neuropédiatrie, INM, Univ Montpellier, INSERM U 1298, Montpellier, France. Hauptthemen laut MEDLINE: Genetic Therapy, Aromatic-L-Amino-Acid Decarboxylases, Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinischen Fakultät Heidelberg, Universität Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The autosomal recessive defect of aromatic L‐amino acid decarboxylase (AADC) leads to a severe neurological disorder with manifestation in infancy due to a pronounced, combined deficiency of dopamine, serotonin and catecholamines. The success of conventional drug treatment is very limited, especially in patients with a severe phenotype. The development of an intracerebral AAV2‐based gene delivery targeting the putamen or substantia nigra started more than 10 years ago. Recently, the putaminally‐delivered construct, Eladocagene exuparvovec has been approved by the European Medicines Agency and by the British Medicines and Healthcare products Regulatory Agency. This now available gene therapy provides for the first time also for AADC deficiency (AADCD) a causal therapy, leading this disorder into a new therapeutic era. By using a standardized Delphi approach members of the International Working Group on Neurotransmitter related Disorders (iNTD) developed structural requirements and recommendations for the preparation, management and follow‐up of AADC deficiency patients who undergo gene therapy. This statement underlines the necessity of a framework for a quality‐assured application of AADCD gene therapy including Eladocagene exuparvovec. Treatment requires prehospital, inpatient and posthospital care by a multidisciplinary team in a specialized and qualified therapy center. Due to lack of data on long‐term outcomes and the comparative efficacy of alternative stereotactic procedures and brain target sites, a structured follow‐up plan and systematic documentation of outcomes in a suitable, industry‐independent registry study are necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyAromatic-L-Amino-Acid DecarboxylasesAmino Acid Metabolism, Inborn ErrorsHumansFollow-Up StudiesGenetic Vectors

Stichwörter der Autor:innen

AADCDAromatic L‐amino acid decarboxylaseEladocagene exuparvovecgene therapyiNTD registryneurotransmitter

Substanzen

Aromatic-L-Amino-Acid Decarboxylases

Autor:innen und Institutionen

  • CHU Montpellier, Département de Neuropédiatrie, INM, Univ Montpellier, INSERM U 1298, Montpellier, France.
  • Division of Child Neurology and Metabolic Medicine, University Children's Hospital Heidelberg, Germany.
  • Institute Human Genetics, University Children's Hospital Heidelberg, Germany.
  • AADC Research Trust, Caterham, UK.
  • Department of Pediatric Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Human Neuroscience-Unit of Child Neurology and Psychiatry, University of Rome La Sapienza.

ORCID-Profile: Thomas Opladen, Oya Kuseyri Hübschmann

Förderung

  • Medizinischen Fakultät Heidelberg, Universität Heidelberg

Zitieren

APA

Roubertie, A., Opladen, T., Brennenstuhl, H., Kuseyri Hübschmann, O., Flint, L., Willemsen, M. A., Leuzzi, V., Cazorla, A. G., Kurian, M. A., François-Heude, M. C., Hwu, P., Zeev, B. B., Kiening, K., Roujeau, T., Pons, R., & Pearson, T. S. (2024). Gene therapy for aromatic L‐amino acid decarboxylase deficiency: Requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47(3), 463-475. https://doi.org/10.1002/jimd.12649

Vancouver

Roubertie A, Opladen T, Brennenstuhl H, Kuseyri Hübschmann O, Flint L, Willemsen MA, et al. Gene therapy for aromatic L‐amino acid decarboxylase deficiency: Requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease. 2024;47(3):463-475. doi:10.1002/jimd.12649

BibTeX
@article{Roubertie2024,
  author = {Roubertie, Agathe and Opladen, Thomas and Brennenstuhl, Heiko and Kuseyri Hübschmann, Oya and Flint, Lisa and Willemsen, Michel A and Leuzzi, Vincenzo and Cazorla, Angels Garcia and Kurian, Manju A and François-Heude, Marie Céline and Hwu, Paul and Zeev, Bruria Ben and Kiening, Karl and Roujeau, Thomas and Pons, Roser and Pearson, Toni S},
  title = {Gene therapy for aromatic L‐amino acid decarboxylase deficiency: Requirements for safe application and knowledge‐generating follow‐up},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  volume = {47},
  number = {3},
  pages = {463--475},
  doi = {10.1002/jimd.12649}
}
Kostenlos starten →